Skip to main content
MED
NYSE Manufacturing

Medifast Director Kiai Parsa Buys 94,036 Shares for $1.13M in Open-Market Trades

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Positive
Importance info
7
Price
$11.475
Mkt Cap
$128.376M
52W Low
$9.22
52W High
$13.63
52W Position info
24% above low
Off High info
16% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

MED sits 24% above its 52-week low of $9.22.

Summary

Medifast director Kiai Parsa bought 94,036 shares for $1.13 million in open-market trades on November 18-19, raising his indirect stake to 804,221 shares. It is his third disclosed purchase since August, made while the company works through a restructuring and a 19.4% revenue decline.


Key Events · Ownership and Investor Activity · MED

  • Director Buys 94,036 Shares for $1.13M

    Kiai Parsa executed four open-market purchases on 2026-11-18 and 2026-11-19 totaling 94,036 shares for $1,133,816, at prices of $12.05-$12.16.

  • Stake Rises to 804,221 Shares

    Post-transaction indirect holdings reached 804,221 shares, held through Steamboat Capital Partners Master Fund and Steamboat Capital Partners II.

  • Third Purchase Since August

    The purchase follows buys of 43,150 shares in August and 5,557 shares on October 28, continuing a pattern of accumulation by the same director.

  • Buying Into a Restructuring

    The purchase comes after Q3 2026 revenue fell 19.4% to $72.0 million and the company posted a $17.5 million net loss including $15.4 million of restructuring charges.


Analysis · MED · Manufacturing

A director has put $1.13 million of real money into the stock over two days at $12.05-$12.16 a share, lifting his indirect holdings to 804,221 shares. This is a meaningful open-market purchase, not an option exercise or grant, and it extends a pattern: Parsa bought 43,150 shares in August and 5,557 shares in late October. The buying comes against a weak backdrop — Q3 revenue fell 19.4% to $72.0 million with a $17.5 million net loss — so the purchase is a director adding to his stake while the business is still shrinking. The main caveat is that the shares sit in Steamboat Capital funds he manages, making this an investment-fund manager's conviction rather than an operating executive's.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MED was trading at $11.48 on NYSE in the Manufacturing sector, with a market capitalization of approximately $128.4M. The 52-week trading range was $9.22 to $13.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MED - Latest Insights

MED
Oct 26, 2026, 8:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.87
Real-time Price: $11.65 info
Change: -$0.220 (-2%) info
Market Cap: $128.376M info
MED
Aug 28, 2026, 12:47 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $11.65 info
Change: -$0.300 (-3%) info
Market Cap: $128.376M info
MED
Aug 21, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $11.65 info
Change: -$0.300 (-3%) info
Market Cap: $128.376M info
MED
Aug 21, 2026, 12:35 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.56
Real-time Price: $11.65 info
Change: +$0.090 (+0.78%) info
Market Cap: $128.376M info
MED
Aug 03, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.80
Real-time Price: $11.65 info
Change: -$1.15 (-9%) info
Market Cap: $128.376M info